Palomino Laboratories Inc. PALX
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 3.85M | 3.49M | -- | -- | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.96M | 3.93M | -- | -- | -- |
| Operating Income | -4.96M | -3.93M | -- | -- | -- |
| Income Before Tax | -5.18M | -3.42M | -- | -- | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.18 | -3.42 | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.18M | -3.42M | -- | -- | -- |
| EBIT | -4.96M | -3.93M | -- | -- | -- |
| EBITDA | -2.59M | -1.24M | -- | -- | -- |
| EPS Basic | -0.71 | -0.50 | -- | -- | -- |
| Normalized Basic EPS | -0.44 | -0.31 | -- | -- | -- |
| EPS Diluted | -0.71 | -0.50 | -- | -- | -- |
| Normalized Diluted EPS | -0.44 | -0.31 | -- | -- | -- |
| Average Basic Shares Outstanding | 62.35M | 43.12M | -- | -- | -- |
| Average Diluted Shares Outstanding | 62.35M | 43.12M | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |